Saturday, July 11, 2026

Drug profile · INN

ruboxistaurin

ruboxistaurin (ARXXANT) is a protein kinase c beta inhibitor.

EMA: application withdrawn
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ruboxistaurin
Class
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

ruboxistaurin (ARXXANT) is a protein kinase c beta inhibitor.

Key facts

INN ruboxistaurin
Brand ARXXANT
Mechanism Protein kinase C beta inhibitor
Target Protein kinase C beta type

Mechanism of action

Protein kinase C beta inhibitor

Primary target: Protein kinase C beta type

Approval history

Authority Status Date
EMA application withdrawn

Frequently asked questions

What is ruboxistaurin?

ruboxistaurin (ARXXANT) is a protein kinase c beta inhibitor.

What is the brand name for ruboxistaurin?

ARXXANT is a marketed brand name for ruboxistaurin. Check FDA Drugs@FDA for the current US label holder and prescribing information.